Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.

Heatwole C, Bode R, Johnson N, Dekdebrun J, Dilek N, Heatwole M, Hilbert JE, Luebbe E, Martens W, Mcdermott MP, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley R 3rd.

Muscle Nerve. 2014 Jun;49(6):906-14. doi: 10.1002/mus.24097.

PMID:
24142420
2.

Myotonic dystrophy health index: Correlations with clinical tests and patient function.

Heatwole C, Bode R, Johnson NE, Dekdebrun J, Dilek N, Eichinger K, Hilbert JE, Logigian E, Luebbe E, Martens W, Mcdermott MP, Pandya S, Puwanant A, Rothrock N, Thornton C, Vickrey BG, Victorson D, Moxley RT 3rd.

Muscle Nerve. 2016 Feb;53(2):183-90. doi: 10.1002/mus.24725.

PMID:
26044513
3.

Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ).

Hermans MC, Faber CG, De Baets MH, de Die-Smulders CE, Merkies IS.

Neuromuscul Disord. 2010 May;20(5):310-8. doi: 10.1016/j.nmd.2010.03.010.

PMID:
20363134
4.

Measurement of participation in myotonic dystrophy: reliability of the LIFE-H.

Gagnon C, Mathieu J, Noreau L.

Neuromuscul Disord. 2006 Apr;16(4):262-8.

PMID:
16545567
5.

Development of a disability scale for myotonic dystrophy type 1.

Contardi S, Pizza F, Falzone F, D'Alessandro R, Avoni P, Di Stasi V, Montagna P, Liguori R.

Acta Neurol Scand. 2012 Jun;125(6):431-8. doi: 10.1111/j.1600-0404.2011.01587.x.

PMID:
21902674
6.

Fatigue and daytime sleepiness rating scales in myotonic dystrophy: a study of reliability.

Laberge L, Gagnon C, Jean S, Mathieu J.

J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1403-5.

7.

A review of patient reported outcome measures for use in DM1 patients.

Symonds T, Randall JA, Campbell P.

Muscle Nerve. 2016 Nov 11. doi: 10.1002/mus.25469. [Epub ahead of print]

PMID:
27862031
8.

Effects of hand-training in persons with myotonic dystrophy type 1--a randomised controlled cross-over pilot study.

Aldehag A, Jonsson H, Lindblad J, Kottorp A, Ansved T, Kierkegaard M.

Disabil Rehabil. 2013 Oct;35(21):1798-807. doi: 10.3109/09638288.2012.754952.

PMID:
23480644
9.

Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy.

Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P.

Neurology. 2001 Feb 13;56(3):336-40.

PMID:
11171898
10.

Perceived functioning and disability in adults with myotonic dystrophy type 1: a survey according to the International Classification Of Functioning, Disability and Health.

Kierkegaard M, Harms-Ringdahl K, Widén Holmqvist L, Tollbäck A.

J Rehabil Med. 2009 Jun;41(7):512-20. doi: 10.2340/16501977-0376.

11.

Reconstructing the Rasch-Built Myotonic Dystrophy Type 1 Activity and Participation Scale.

Hermans MC, Hoeijmakers JG, Faber CG, Merkies IS.

PLoS One. 2015 Oct 20;10(10):e0139944. doi: 10.1371/journal.pone.0139944.

12.

The use of muscle strength assessed with handheld dynamometers as a non-invasive biological marker in myotonic dystrophy type 1 patients: a multicenter study.

Hébert LJ, Remec JF, Saulnier J, Vial C, Puymirat J.

BMC Musculoskelet Disord. 2010 Apr 18;11:72. doi: 10.1186/1471-2474-11-72.

13.

A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).

Whalley D, McKenna SP, Dewar AL, Erdman RA, Kohlmann T, Niero M, Cook SA, Crickx B, Herdman MJ, Frech F, Van Assche D.

Br J Dermatol. 2004 Feb;150(2):274-83.

PMID:
14996098
14.
15.

Decreased hypocretin-1 (Orexin-A) levels in the cerebrospinal fluid of patients with myotonic dystrophy and excessive daytime sleepiness.

Martínez-Rodríguez JE, Lin L, Iranzo A, Genis D, Martí MJ, Santamaria J, Mignot E.

Sleep. 2003 May 1;26(3):287-90.

PMID:
12749547
16.

Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study.

Baldanzi S, Bevilacqua F, Lorio R, Volpi L, Simoncini C, Petrucci A, Cosottini M, Massimetti G, Tognoni G, Ricci G, Angelini C, Siciliano G.

Orphanet J Rare Dis. 2016 Apr 4;11:34. doi: 10.1186/s13023-016-0417-z.

17.

A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.

Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, Maccarone M, Carton L, Otsa K, Sooäär I, Heiberg T, Bertheussen H, Cañete JD, Sánchez Lombarte A, Balanescu A, Dinte A, de Vlam K, Smolen JS, Stamm T, Niedermayer D, Békés G, Veale D, Helliwell P, Parkinson A, Luger T, Kvien TK; EULAR PsAID Taskforce..

Ann Rheum Dis. 2014 Jun;73(6):1012-9. doi: 10.1136/annrheumdis-2014-205207.

PMID:
24790067
18.

Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy.

Kierkegaard M, Tollbäck A.

Neuromuscul Disord. 2007 Dec;17(11-12):943-9.

PMID:
17869516
19.

Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2.

Tieleman AA, Knoop H, van de Logt AE, Bleijenberg G, van Engelen BG, Overeem S.

J Neurol Neurosurg Psychiatry. 2010 Sep;81(9):963-7. doi: 10.1136/jnnp.2009.192591.

PMID:
20798200
20.

Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1).

Heatwole C, Bode R, Johnson N, Quinn C, Martens W, McDermott MP, Rothrock N, Thornton C, Vickrey B, Victorson D, Moxley R 3rd.

Neurology. 2012 Jul 24;79(4):348-57. doi: 10.1212/WNL.0b013e318260cbe6. Erratum in: Neurology. 2012 Sep 25;79(13):1411.

Items per page

Supplemental Content

Support Center